BioCryst's Orladeyo Launch Overshadowed by FDA Hold on PNH Asset

Although BioCryst probably wanted to tout the success of its Orladeyo launch in its first-quarter financial report, it was overshadowed by the news that the U.S. Food and Drug Administration had placed a partial clinical hold on three of its clinical trials evaluating a development-stage asset, BCX9930.